Shares of Genprex Inc (NASDAQ:GNPX) have earned a consensus broker rating score of 2.00 (Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating and one has given a strong buy rating to the company. Genprex’s rating score has declined by 100% from 90 days ago as a result of a number of analysts’ upgrades and downgrades.
Brokers have set a 1-year consensus target price of $9.00 for the company and are forecasting that the company will post ($0.21) earnings per share for the current quarter, according to Zacks. Zacks has also given Genprex an industry rank of 70 out of 256 based on the ratings given to related companies.
Several brokerages have recently weighed in on GNPX. Noble Financial began coverage on shares of Genprex in a report on Monday, April 29th. They set an “outperform” rating and a $5.00 price objective on the stock. Zacks Investment Research downgraded shares of Genprex from a “hold” rating to a “sell” rating in a research report on Thursday, April 18th. Finally, Maxim Group downgraded shares of Genprex from a “buy” rating to a “hold” rating in a research report on Monday, April 1st.
Genprex (NASDAQ:GNPX) last released its earnings results on Monday, April 1st. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.09). As a group, equities analysts predict that Genprex will post -0.74 earnings per share for the current year.
An institutional investor recently bought a new position in Genprex stock. Renaissance Technologies LLC bought a new position in shares of Genprex Inc (NASDAQ:GNPX) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 26,740 shares of the company’s stock, valued at approximately $42,000. Renaissance Technologies LLC owned approximately 0.17% of Genprex as of its most recent filing with the Securities and Exchange Commission. 5.77% of the stock is owned by institutional investors.
Genprex Company Profile
Genprex, Inc operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells.
Read More: Forex
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.